On April 7, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this segment, Mr. Klemp highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. Annamycin was specifically designed to avoid cardiac damage, and has demonstrated this advantage across preclinical and clinical studies. This non-cardiotoxic profile could expand treatment options for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced solid tumors, particularly those previously treated with anthracyclines or with existing cardiac risk factors. Mr. Klemp also notes the potential benefits for physicians in enabling more flexible treatment strategies, as well as the favorable regulatory and commercial implications of a differentiated safety profile. As the Company advances its MIRACLE Study, he underscores that Annamycin’s unique design may position it as a promising new option in oncology, with the potential to reshape the use of anthracyclines in modern cancer care.

Access the CEO Corner on the Company’s website.

(Press release, Moleculin, APR 7, 2026, View Source [SID1234664208])